After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum
Investors shouldn't give up on Gilead's Hep. C drug, Cramer says.
Gilead (GILD) stock was down in pre-market trading on Tuesday after Leerink cut its rating on shares to 'market perform.'
Here are Tuesday's top research calls, including upgrades for AutoZone and Eli Lilly, and downgrades for J.M. Smucker and Toll Brothers.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.